Pfizer Stops Covid Pill Trial After Latest Results Showed It DID NOT Reduce Symptoms, Hospitalizations, or Deaths
According to a statement by the company, Pfizer has stopped COVID pill trial after the latest results showed that it did not reduce symptoms, hospitalizations and deaths.
Pfizer has stated it will halt participation in a clinical trial for Paxlovid, its COVID-19 antiviral medication, for standard-risk COVID-19 patients after the most recent findings revealed the medication did not numerically greatly lower symptoms, hospitalizations, or fatalities.
In more than 65 nations, including the United States, Paxlovid, a combination of the antivirals nirmatrelvir and ritonavir, is presently approved or authorized for conditional or emergency use in the treatment of COVID-19 patients at high risk of developing severe illness, including hospitalization or death.
According to a statement made by Pfizer on June 14, it will “cease enrollment into the EPIC-SR trial due to low rate of hospitalization or death in the standard-risk population.”
The business asserted that it will nonetheless incorporate the new information in its impending application to the U.S. Food and Drug Administration (FDA) to request complete authorization for the administration of Paxlovid to high-risk COVID-19 individuals.
“The company will focus efforts on generating further data on PAXLOVID in vulnerable populations, including longer treatment durations in immunocompromised individuals, as well as exploring other clinical development opportunities, such as its potential use in hospitalized patients with severe disease,” Pfizer added.
Patients with COVID-19 who do not have risk factors for serious illness are referred to be standard-risk patients. They may or may not have received vaccinations.
Results From Trial
Paxlovid and a placebo were compared in the August 2021 beginning of the EPIC-SR study in adult patients with symptomatic COVID-19 who are not hospitalized and “are at low risk of progressing to severe illness.”
Pfizer revealed that Paxlovid results fell short of the study’s objective of “self-reported, sustained alleviation of all symptoms for four consecutive days, as compared to placebo” in December 2021.
When contrasted to the placebo group (10 out of 426 hospitalized, with no deaths), the Paxlovid group’s hospitalizations were reduced by 70% (3 out of 428 hospitalizations, with no deaths). But because the findings were not statistically significant, it is possible that chance played a role.
On June 14, Pfizer revealed that an updated assessment of 1,153 patients who had been enrolled through December 2021 had revealed a 51 percent difference between the two groups in terms of hospitalization or death, with five out of 576 patients in the Paxlovid group and 10 out of 569 in the placebo group necessitating hospitalization or passing away. Once more, the outcomes lacked statistical significance.
According to the manufacturer, there was just one death in the placebo group whereas there were none among the patients who took Paxlovid.
People who had received all of their vaccinations and had at least one risk factor for developing severe COVID-19 were initially included in the EPIC-SR investigation; however, after Paxlovid was approved for the cohort in December 2021, this cohort was no longer included in the study. Pfizer then changed its research eligibility requirements to permit participants whose most recent vaccination was 12 months or more ago.
There was a 57 percent risk reduction for hospitalization or death, with three out of 361 in the Paxlovid group and seven out of 360 in the placebo group requiring to be hospitalized or passing away, according to a sub-group analysis of 721 vaccinated individuals with at least one risk factor for progression to severe COVID-19. Pfizer reported that the results were not statistically significant.
Additionally, Paxlovid exhibited a non-significant 62 percent daily reduction in COVID-19-related medical visits across all patients as compared to placebo.
According to a statement from Pfizer’s CEO and chairman, Albert Bourla, the company’s preliminary research findings “support the efficacy and safety profile for PAXLOVID in the treatment of mild-to-moderate COVID-19 patients with at least one risk factor for progressing to severe COVID-19, regardless of vaccination status.”
“With up to 40–50 [percent] of people around the world estimated to be high risk, we believe there remains a significant unmet need for treatment options to help combat this disease, and we will continue to prioritize efforts to advance the development of PAXLOVID,” he added.
Paxlovid decreases COVID-19 hospitalization and mortality by 46%, according to data from a retrospective cohort study conducted in Israel in early June among a highly immunized community. The study said the drug was “more effective in older patients, immunosuppressed patients, and patients with underlying neurological or cardiovascular disease.”
The antiviral medication Paxlovid was not successful in avoiding symptomatic COVID-19 infection in household contacts of the COVID-19 patient who took the tablet, according to a second study in which it failed to yield a statistically significant outcome. Pfizer made this announcement in April.
The United States ended up spending more than $10 billion to purchase 20 million courses of Paxlovid from Pfizer, and the White House has been requesting additional funding from Congress to sustain the purchase of additional courses of the antiviral medication, as well as other treatments and booster doses of vaccines.
The Centers for Disease Control and Prevention (CDC) issued a warning in late May that a few individuals taking Paxlovid may encounter a rebound in COVID-19 symptoms, which means they may experience symptoms again after their symptoms have subsided or test positive for COVID-19 after testing negative.
When the rebound occurred, the CDC stated that it might not have been caused by the medication and that it “may be part of the natural history of SARS-CoV-2” in certain individuals, “independent of treatment with Paxlovid and regardless of vaccination status.”
GreatGameIndia is being actively targeted by powerful forces who do not wish us to survive. Your contribution, however small help us keep afloat. We accept voluntary payment for the content available for free on this website via UPI, PayPal and Bitcoin.
Image by Kches16414, CC BY-SA 4.0, via Wikimedia Commons.
Most “Conservative” News Outlets Are on the Big Tech Teat
Not long ago, conservative media was not beholden to anyone. Today, most sites are stuck on the Big Tech gravy train.
I’ll keep this short. The rise of Pandemic Panic Theater, massive voter fraud, and other “taboo” topics have neutered a majority of conservative news sites. You’ll notice they are very careful about what topics they tackle. Sure, they’ll attack Critical Race Theory, Antifa, and the Biden-Harris regime, but you won’t see them going after George Soros, Bill Gates, the World Economic Forum, or the Deep State, among others.
The reason is simple. They are beholden to Big Tech, and Big Tech doesn’t allow certain topics to be discussed or they’ll cut you off. Far too many conservative news outlets rely on Google, Facebook, and Twitter for the bulk of their traffic. They depend on big checks from Google ads to keep the sites running. I don’t necessarily hold it against them. We all do what we need to do to survive. I just wish more would do like we have, which is to cut out Big Tech altogether.
We don’t get Google checks. We don’t have Facebook or Twitter buttons on our stories. We don’t have a YouTube Channel (banned), an Instagram profile (never made one), or a TikTok (no thanks, CCP). We’re not perfect, but we’re doing everything we can to not owe anything to anyone… other than our readers. We owe YOU the truth. We owe YOU the facts that others won’t reveal about topics that others won’t tackle. And we owe America, this great land that allows us to take hold of these opportunities.
Like I said, I don’t hold other conservative sites under too much scrutiny over their choices. It’s easy for people to point fingers when we’re not the ones paying their bills or supporting their families. I just wish there were more who would make the bold move. Today, only a handful of other major conservative news outlets have broken free from the Big Tech teat. Of course, we need help.
The best way you can help us grow and continue to bring proper news and opinions to the people is by donating. We appreciate everything, whether a dollar or $10,000. Anything brings us closer to a point of stability when we can hire writers, editors, and support staff to make the America First message louder. Our Giving Fuel page makes it easy to donate one-time or monthly. Alternatively, you can donate through PayPal or Bitcoin as well. Bitcoin: 3A1ELVhGgrwrypwTJhPwnaTVGmuqyQrMB8
Our network is currently comprised of nine sites:
We are also building partnerships with great conservative sites like The Liberty Daily and The Epoch Times to advance the message as loudly as possible, and we’re always looking for others with which to partner.
Some of our content is spread across multiple sites. Other pieces of content are unique. We write most of what we post but we also draw from those willing to allow us to share their quality articles, videos, and podcasts. We collect the best content from fellow conservative sites that give us permission to republish them. We’re not ego-driven; I’d much rather post a properly attributed story written by experts like Dr. Joseph Mercola or Natural News than rewrite it like so many outlets like to do. We’re not here to take credit. We’re here to spread the truth.
While donations are the best way to help, you can also support us by buying through our sponsors:
- MyPillow: Use promo code “NOQ” to get up to 66% off AND you’ll be helping a patriotic, America First company.
- ZStack: Improve your immune system with the Z-Stack protocol or rejuvenate your body from vaccines or shedding with Z-DTox by Dr. Vladimir Zelenko.
- OurGoldGuy: Tell them JD sent you in your request to buy gold and it will help us… AND (wait for it) you’ll be helping a patriotic, America First company.
- MyPatriotSupply: Stock up on long-term food, survival gear, and other things that you’ll need just in case things don’t recover and we keep heading towards apocalypse.
We know we could make a lot more money if we sold out like so many “conservative” publications out there. You won’t find Google ads on our site for a reason. Yes, they’re lucrative, but I don’t like getting paid by minions of Satan (I don’t like Google very much if you couldn’t tell).
Time is short. As the world spirals towards The Great Reset, the need for truthful journalism has never been greater. But in these times, we need as many conservative media voices as possible. Please help keep NOQ Report and the other sites in the network going. Our promise is this: We will never sell out America. If that means we’re going to struggle for a while or even indefinitely, so be it. Integrity first. Truth first. America first.
Thank you and God Bless,
JD Rucker
Bitcoin: 32SeW2Ajn86g4dATWtWreABhEkiqxsKUGn
All ORIGINAL content on this site is © 2021 NOQ Report. All REPUBLISHED content has received direct or implied permission for reproduction.
With that said, our content may be reproduced and distributed as long as it has a link to the original source and the author is credited prominently. We don’t mind you using our content as long as you help out by giving us credit with a prominent link. If you feel like giving us a tip for the content, we will not object!
JD Rucker – EIC
@jdrucker
This article has been archived for your research. The original version from Based Underground can be found here.
